Diabetic endotheliopathy: RNA-binding proteins as new therapeutic targets

Victoria A. Cornelius, Andrew Yacoub, Sophia Kelaini, Andriana Margariti*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Diabetic Endotheliopathy is widely regarded as a principal contributor to cardiovascular disease pathogenesis in individuals with Diabetes mellitus. The endothelium, the innermost lining of blood vessels, consists of an extensive monolayer of endothelial cells. Previously regarded as an interface, the endothelium is now accepted as an organ system with critical roles in vascular health; its dysfunction therefore is detrimental. Endothelial dysfunction induces blood vessel damage resulting in a restriction of blood and oxygen supply to tissues, the central pathology of cardiovascular disease. Hyperglycemic conditions have repeatedly been isolated as a pivotal inducer of endothelial cell dysfunction. Numerous studies have since proven hyperglycemic conditions to significantly alter the gene expression profile of endothelial cells, with this being largely attributable to the post-transcriptional regulation of RNA-binding proteins. In particular, the RBP Quaking-7 has recently emerged as a crucial mediator of diabetic endotheliopathy, with great potential to become a therapeutic target.
Original languageEnglish
Article number105907
JournalInternational Journal of Biochemistry and Cell Biology
Early online date26 Dec 2020
Publication statusPublished - Feb 2021

Bibliographical note

Funding Information:
This work was supported by grants from the British Heart Foundation and the Department for the Economy studentships NI .

Publisher Copyright:
© 2020 Elsevier Ltd

Copyright 2020 Elsevier B.V., All rights reserved.


  • Cardiovascular disease
  • Diabetes
  • Hyperglycemia
  • Diabetic endotheliopathy
  • RNA-binding proteins
  • Quaking

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology


Dive into the research topics of 'Diabetic endotheliopathy: RNA-binding proteins as new therapeutic targets'. Together they form a unique fingerprint.

Cite this